WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 3 fonti

Treatment Intensification Slows Metastatic Hormone-Sensitive Prostate Cancer

Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alterations

Raccontata da

morningstar.com

medpagetoday.com

pharmaceutical-technology.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo1 mesi fa

Treatment Intensification Slows Metastatic Hormone-Sensitive Prostate Cancer

Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alterations

morningstar.com1 mesi fa

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate…

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

Leggi questa versione → originale

Timeline cronologica

sabato 30 maggio 2026·morningstar.com
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
domenica 31 maggio 2026·medpagetoday.com
Treatment Intensification Slows Metastatic Hormone-Sensitive Prostate Cancer
Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alterations

pharmaceutical-technology.com1 mesi fa

ASCO 2026: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC - Pharmaceutical Technology

At ASCO 2026, Pfizer presented top line data for the Phase III TALAPRO-3 clinical trial, evaluating Talzenna combined with Xtandi.

Leggi questa versione → originale

martedì 2 giugno 2026·

pharmaceutical-technology.com

ASCO 2026: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC - Pharmaceutical Technology

At ASCO 2026, Pfizer presented top line data for the Phase III TALAPRO-3 clinical trial, evaluating Talzenna combined with Xtandi.